BindingDB logo
myBDB logout

23 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28222316 165 Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.EBI De Montfort University
27265259 16 Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.EBI Whittier College
26222195 56 A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2.EBI Xavier University of Louisiana
25799264 94 Design and Synthesis of Newa-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.EBI Shanghai Jiao Tong University
25089810 79 Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.EBI National Taiwan University
23806553 7 Discovery of triazines as potent, selective and orally active PDE4 inhibitors.EBI BioCrea GmbH
23600958 57 Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1.EBI Xavier University of Louisiana
16248836 154 Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.EBI F. Hoffmann-La Roche Ltd.
22863525 36 Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1.EBI Poznan University of Medical Sciences
18462007 7 Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.EBI Universidade Federal de Minas Gerais
17544277 29 Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.EBI University of Maryland
12852960 48 Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.EBI National Research Institute of Chinese Medicine
22266038 55 Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.EBI AstraZeneca
22079757 13 Discovery of a novel class of aldol-derived 1,2,3-triazoles: potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).EBI McMaster University
21482471 28 Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.EBI University of Crete
21411321 28 Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.EBI Merck Research Laboratories
20813430 5 Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays.EBI Instituto Politécnico Nacional
20696580 54 Selective inhibition of methoxyflavonoids on human CYP1B1 activity.EBI University of Shizuoka
16631366 26 Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.EBI AstraZeneca
11754588 39 Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.EBI Seoul National University